Product and R&D
Combined with the clinical needs of China, integrate the global R & D resources to obtain therapeutic new drugs, based on the Chinese market, transform the traditional sales network, and build an advantageous treatment drug industry platform integrating research, production and marketing.
About Xerclear® - P...
In 2009, Xerclear® (Zoviduo®) was approved for the treatment of labial herpes. The marketing rights to Xerclear® in the USA, Canada and Mexico were divested in 2010,
View details > >
Temodex - Product in...
Temodex is an experimental medicine for treatment of brain cancers , a formulation of temozolomide and a biodegradable polymer.
View details > >
XERCLEAR...
View details > >Subsidiaries of the company
News and information
Cooperative partner
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The company is investing in indication areas where available therapies are limited or missing and there are great opportunities to offer significant improveme
Double Bond is a pharmaceutical company which develops and commercializes innovative first-in-class approaches for treatment of cancers, infections, autoimmune diseases and other life-threatening disorders.
a company duly incorporated and organized under the laws of Sweden, having its registered address at Medicon Village, Scheelevagen 2, SE-223 81 Lund, Sweden (“CLS”); CLS is engaged in the research and development of minimally invasive methods for cancer t
Copyright 2018-2022 GRANDEURBIO. All rights reserved